Gilead Sciences (GILD) Inventory Average (2009 - 2026)
Gilead Sciences' (GILD) quarterly Inventory Average came in at $1.8 billion in Q1 2026, up 6.31% YoY from $1.7 billion in Q1 2025, and up 3.62% on a QoQ basis from $1.8 billion in Q4 2025.
Gilead Sciences (GILD) Inventory Average (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Inventory Average data on file, last reported at $1.8 billion in Q1 2026.
- Quarterly Inventory Average rose 6.31% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 6.31% YoY) and the FY2025 annual result came in at $1.7 billion, changed 0.37% from the prior year.
- Inventory Average rose to $1.8 billion in Q1 2026, from $1.8 billion in the prior quarter.
- In the past five years, Inventory Average ranged from a high of $1.9 billion in Q3 2024 to a low of $1.5 billion in Q3 2022.
- A 5-year average of $1.7 billion and a median of $1.7 billion in 2025 frame the typical range for Inventory Average.
- Annual changes were most pronounced in 2022 — Inventory Average dropped 16.19% — and 2024, when it grew 20.88%.
- Tracing GILD's Inventory Average over 5 years: stood at $1.5 billion in 2022, then increased by 16.16% to $1.7 billion in 2023, then grew by 3.74% to $1.8 billion in 2024, then fell by 0.56% to $1.8 billion in 2025, then gained by 3.62% to $1.8 billion in 2026.
- The last three Inventory Average figures came in at $1.8 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.8 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.19 Bn | 631.43 Bn | 17.26 Bn | 14.86 Bn |
| 2 | AbbVie | 470.70 Bn | 464.13 Bn | 12.70 Bn | 5.09 Bn |
| 3 | Merck | 379.55 Bn | 372.41 Bn | 12.21 Bn | 6.34 Bn |
| 4 | Novartis Ag | 302.93 Bn | 295.24 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.73 Bn | 252.83 Bn | 12.86 Bn | 6.75 Bn |
| 6 | Amgen | 236.90 Bn | 222.91 Bn | 7.24 Bn | 6.20 Bn |
| 7 | Gilead Sciences | 182.87 Bn | 179.69 Bn | 6.22 Bn | 1.93 Bn |
| 8 | Pfizer | 161.71 Bn | 150.01 Bn | 10.94 Bn | 10.31 Bn |
| 9 | Gsk | 105.60 Bn | 101.43 Bn | 8.24 Bn | 8.36 Bn |
| 10 | Sanofi | 55.13 Bn | 47.75 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.93 Bn |
| Mar 31, 2026 | 1.84 Bn |
| Dec 31, 2025 | 1.78 Bn |
| Sep 30, 2025 | 1.81 Bn |
| Jun 30, 2025 | 1.79 Bn |
| Mar 31, 2025 | 1.73 Bn |
| Dec 31, 2024 | 1.79 Bn |
| Sep 30, 2024 | 1.95 Bn |
| Jun 30, 2024 | 1.94 Bn |
| Mar 31, 2024 | 1.82 Bn |
| Dec 31, 2023 | 1.73 Bn |
| Sep 30, 2023 | 1.65 Bn |
| Jun 30, 2023 | 1.60 Bn |
| Mar 31, 2023 | 1.54 Bn |
| Dec 31, 2022 | 1.49 Bn |
| Sep 30, 2022 | 1.48 Bn |
| Jun 30, 2022 | 1.49 Bn |
| Mar 31, 2022 | 1.55 Bn |
| Dec 31, 2021 | 1.65 Bn |
| Sep 30, 2021 | 1.72 Bn |